Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045

On June 16, 2026, Cognition Therapeutics, Inc., a company listed on NASDAQ under the ticker symbol CGTX, specializing in developing drugs for neurodegenerative conditions, shared the reception of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) pertaining to patent application 19/563,468. This marks a significant milestone for the clinical-stage company in its mission to advance treatments for such disorders.